The rapid decrease in DNA sequencing cost is revolutionizing medicine and science. In medicine, 11 genome sequencing has revealed millions of missense variants that change protein sequences, yet we 12 only understand the molecular and phenotypic consequences of a small fraction. • Human exome sequencing is revealing millions of missense variants that change protein 25 sequences, but their phenotypic consequences are mostly unknown 26
• Human exome sequencing is revealing millions of missense variants that change protein 25 sequences, but their phenotypic consequences are mostly unknown 26
• Deep mutational scanning and other high-throughput experiments provide simultaneous insights 27 into the effects of thousands of variants 28
• Loss of protein stability is a common origin of inherited diseases, and computational predictions 29 of protein stability are useful for assessing variant consequences 30
• Cellular protein quality control provides a mechanistic link between altered protein stability and 31 cellular protein levels and degradation 32
• Computational biophysics, evolutionary sequence analyses and machine learning methods each 33 provide information about variant consequences and may potentially be combined 34
• Mechanistic models for how mutations give rise to disease provide a starting point for 35 therapeutic strategies 36 37
Introduction 38
Technological advances in DNA sequencing have made human genome sequencing on large scales not 39 only feasible, but also affordable. The resulting data avalanche has highlighted the challenge of 40 interpreting the phenotypic consequences of genetic variants [1, 2] . Variant interpretation is particularly 41 challenging since more than half of the distinct variants found in an analysis of >60.000 human exomes 42
were only observed in a single individual [3] and since many diseases have a complex, polygenic origin 43 [4] . Although the problem is difficult and complicated, the potential to improve the understanding, 44 diagnosis and treatment of human diseases is enormous. 45
In this review, we focus on missense variants that result in a change from one amino acid to another 46 (henceforth called variants). Further, we focus on recent efforts to understand and predict the effects 47 these variants have on biophysical properties of proteins, and, consequently, their effect on function. 48
While protein-coding regions only make up ~1.5% of the genome, around 5-10% of hits in genome-49 wide association studies fall into them, although linkage disequilibrium (joint inheritance of elements 50 proximal on a chromosome) makes it challenging to identify precisely which of multiple nearby 51 variants is causal [5] . Beyond diagnosis, we may use existing knowledge of proteins and their cellular 52 pathways to help elucidate the disease-causing mechanisms. Because proteins can be targeted by small 53 molecules or peptides, these insights can potentially open up therapeutic avenues. 54
Interpreting missense variation 55
Missense variants represent over 40% of the unique variants observed in the Exome Aggregation 56
Consortium database [3] , yet their phenotypic consequences are often difficult to predict. This is in 57 contrast to nonsense or frameshift variants that cause large changes to the encoded protein and 58 consequently are usually deleterious. As an example, systematic mutagenesis studies of the highly 59 conserved protein ubiquitin have shown that many single missense mutations only have a minor impact 60 on protein function in a cellular assay [6] . An analysis of similar high-throughput data across multiple 61 proteins suggest that indeed about two thirds of single amino acid changes have only a minor effect on 62 function [7] . Some variants are, however, severely detrimental and cause essentially complete loss of 63
function. An interesting observation from further studies on ubiquitin is that, at least for this protein, 64 there can be substantial variation of the effect of a mutation depending on the cellular status and 65 conditions, so that most variants are detrimental under at least one condition [8] . 66
In a clinical setting it would be useful to have robust methods and sufficient data for interpretation of 67 genetic variants and accurate classifications of whether they are pathogenic or benign likely to involve hydrophobic regions that are buried in the native protein, but exposed in misfolded 141 proteins ( Fig. 1) . We refer the reader to recent reviews of the role and components of the PQC that are 142 important to the degradation of misfolded proteins [34, 35] . 143
In the context of disease-causing mutations, a key question is how much structural destabilization is 144 tolerated before the PQC system kicks in? Recently, it was shown that the degree of protein 145 destabilization correlates with the turnover rate in the Lynch-syndrome related protein MSH2 Fig. 2 ). VAMP-seq measures the impact of variants on the steady-state cellular abundance 198 of a protein [41] . Here, a library of variants of the protein of interest is fused to GFP (Fig. 2a) . Then, 199 the library is expressed in cultured mammalian cells such that each cell expresses one and only one 200 variant (Fig. 2b) . The stability of the variant dictates the stability of the GFP fusion, so each cell's GFP 201 fluorescence reports on the abundance of the protein variant. Cells are sorted into bins based on their 202 fluorescence, next-generation sequencing is used determine the frequency of every variant in each bin, 203
and variant frequencies are used to compute abundance scores (Fig. 2c) . Thus, a single VAMP-seq 204 experiment provides quantitative abundance data for thousands of variants simultaneously and enables 205 one to separate mutations with modest effects on stability from those that are substantially destabilizing 206 (Fig. 2d) . 207
In the context of enabling computational prediction methods, it is worth highlighting that a single 208 VAMP-seq experiment provides information about a number of variants comparable in size the entire 209 database used to train current state-of-the-art models for predicting protein stability [42, 43] (Fig. 2e) . 210
Another advantage is that DMS experiments generally target most or all of the 19 possible amino acid 211 substitutions at each position. This comprehensive data is useful in the clinic because it can be used to 212 aid the interpretation of any variant. Moreover, unlike the majority of available biophysical data that is 213 highly biased [44] and mostly consist of side chain truncations to alanine or glycine (Fig. 2e) , 214 comprehensive functional and stability data can both be used to provide insight into a specific protein 215 and can also be used to guide the development of improved pathogenicity prediction methods. DMS is 216 already a widely-applied method, and will become even more useful as methods for generating and 217 sequencing variant libraries improve and decrease in cost. We also note that DMS and related high-218 throughput experiments may provide very useful information for understanding and improving protein 219 function and stability for example in protein engineering and design [45, 46] . 220
Predicting the consequences of missense variation 221
While experimental testing of variants is expanding in scope and scale, computational predictions of 222 variant consequences will continue to be the only widely applicable method to assess pathogenicity for 223 the foreseeable future. A number of predictors have been trained specifically for this purpose, often 224 using known benign and pathogenic variants [47] . Here, we instead focus on three distinct approaches 225 developed to address more general questions concerning how changes in the protein sequence affect, 226 for example, protein stability or general functional properties. These methods have not been 227 specifically trained on pathogenic variants; instead, they were created to capture thermostability of 228 folding, evolutionary tolerance, and patterns observed in DMS experiments, respectively. To illustrate 229 the outcome and performance of these three classes of prediction methods, we show the results of 230 stability calculations (Fig. 3a) , a sequence likelihood model (Fig. 3b ) and the DMS-based prediction 231 method (Fig. 3c) As an example of the power of using these three prediction paradigms, we show their application to the 274 protein MSH2, where mutations may lead to cancer predisposition (Lynch syndrome) (Fig. 3) The results show clearly that, although these methods have not been trained on population genetics data 283 or disease mutations, they are able to separate known disease-causing variants from benign variants 284 with relatively high accuracy. For example, benign variants generally have modest effects on stability, 285 whereas many pathogenic variants are highly destabilizing. It is also worth noting that only three of the 286 XX pathogenic variants seen in ClinVar have actually been observed in the ~150.000 genome and 287 exome sequences available in gnomAD. Thus, there is a clear trend that more common population 288 variants are predicted to have milder effects, whereas many uncommon variants and pathogenic 289 variants are predicted to have more dramatic effects (Fig. 3A) . These observations imply that there is a 290 clear difference in the distribution of predicted scores between benign and pathogenic variants (Fig.  291 3B) which in turn can be transformed into relatively accurate predictions (Fig. 3C) . Nonetheless, the 292 analyses also show that these predictions of functional effects are not yet alone sufficient to fully 293 separate benign from pathogenic variation. 294
Therapeutic possibilities 295
In addition to the prospect for improved diagnosis via prediction of pathogenicity, the experimental and 296 computational studies discussed above provide new opportunities for treatment of diseases. For 297 mutations that gives rise to disease via loss of stability, intracellular degradation and thereby loss of 298 function, it might be possible to rescue function via restabilization. In particular, because the PQC is 299 overzealous in targeting potentially functional, but mildly destabilized proteins, many disease-causing 300 variants might be sufficiently functional that pathogenicity could potentially be averted if the proteins 301 were stabilized [29] (Fig. 4) . 302
The most dramatic approach is perhaps to inhibit the proteasome, and proteasome inhibitors are indeed 303 already approved drugs [62] . In many cases, a more direct and elegant approach might be to target the 304 components in the PQC that are relevant for degrading a specific disease-causing variant. To enable 305 this approach, we need to map in much greater detail the E3 enzymes and chaperones involved in 306 recognizing specific substrates and targeting them for degradation. One of the problems in assessing the importance of loss of stability for disease is that we do not fully 335 understand when and why the current prediction methods fail. This is in part due to the fact that they 336 were trained and benchmarked on a biased dataset that mostly focuses on mutations where a large 337 amino acid is mutated to a smaller one, often alanine or glycine. We expect that unbiased functional 338 data from DMS experiments will be extremely useful in assessing and parameterizing prediction 339 methods for a much wider set of amino acid changes. An important problem to tackle in the future is to 340 map genetic variants on to accurate structural models for the entire human proteome [71] , and to 341 develop prediction methods that are robust towards structural noise in homology models. Finally, an 342 important open question is how the different prediction methods are best combined, and how they can 343 both provide accurate predictions of pathogenicity and aid in developing mechanistic hypotheses for 344 the origin of disease. 345
Outstanding Questions 346
• What are the structural features of the unfolded and misfolded states, and how are they 347 recognized by the PQC system? 348
• illustrate that all three predictors correctly identify many of the pathogenic variants as detrimental, and 578 most of the benign variants as tolerated. The "area under the curve" (AUC) in a receiver operating 579 characteristic (ROC) analysis is 0.91, 0.90, and 0.91 for the three methods, respectively. To address the 580 imbalance between the sizes in the pathogenic and benign datasets, the pathogenic dataset was split in 581 three; these AUCs are averages over these three ROC analyses. 582 
